Table 2. Base–case analysis.
| HomePO | HomeIV | EarlyDC | HospIV | |
|---|---|---|---|---|
| Cost (mean) | $3470 | $4183 | $6115 | $13 557 |
| Cost (95% CI) | $1669–6564 | $2001–7616 | $2471–12 394 | $4592–30 000 |
| IncrC (mean) | — | $713 | $1932 | $9374 |
| Eff (mean) | 0.65 | 0.72 | 0.66 | 0.62 |
| Eff (95% CI) | 0.13–0.91 | 0.18–0.98 | 0.22–0.92 | 0.15–0.94 |
| IncrEff (mean) | — | 0.07 | −0.06 | −0.10 |
| C/E (mean) | $5338 | $5810 | $9265 | $21 866 |
| ICER | — | $10 186 | Dominateda | Dominateda |
Abbreviations: CI=confidence interval; C/E=cost-effectiveness ratio; EarlyDC= treatment at home after an initial observation in hospital; Eff, effectiveness; Effectiveness=quality-adjusted febrile neutropaenia episode (rounded to 2 decimals); HomeIV=outpatient management with intravenous antibiotics; HomePO=outpatient management with oral antibiotics; HospIV=entire in-patient management; IncrC, incremental cost; IncrEff, incremental effectiveness; ICER, incremental cost-effectiveness ratio.
Dominated refers to the finding that this strategy is dominated (e.g. both less effective and more costly than other strategies).
Note: All costs are given in Canadian dollars.
Options are ordered by increasing costs. Option 1 (HomePO) is the baseline reference to calculate incremental costs and effectiveness for option 2 (HomeIV). As option 2 is more effective than option 1, the former one is used as new baseline reference to calculate incremental costs (and effectiveness) for options 3 (EarlyDC) and 4 (HospIV). As options 3 and 4 are less effective and more expensive than option 2, they are both dominated by option 2.